Formulation Development
LIXTE Biotechnology’s Lead Clinical Compound Increases Effectiveness of Cancer Immunotherapy
LIXTE Biotechnology Holdings, Inc. recently announced a recently published article in the journal Cancer Research showed that PP2A, the pharmacologic target of LIXTE’s lead clinical…
Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell & Gene Therapy Development
Catalent recently announced it has expanded the services and capabilities at its facility in Shiga, Japan, to include the storage, kitting, and distribution of advanced…
Transgene & BioInvent Report Positive Phase 1a Data on Oncolytic Virus BT-001 in Solid Tumors
Transgene and BioInvent International AB recently announce positive Phase 1a data on the oncolytic virus BT-001 for the treatment of solid tumors. Treatment with single agent BT-001 in 18 patients has now been….
Oxford BioTherapeutics & Boehringer Ingelheim Agree on 2-Year Extension to their Second Multi-Year Collaboration in Cancer Immunology
Oxford BioTherapeutics Ltd. recently announced it has extended its second multi-year collaboration with Boehringer Ingelheim for an additional 2 years. With this extension, further programs will….
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
Apellis Pharmaceuticals, Inc. recently announced the Phase 2 MERIDIAN study investigating systemic pegcetacoplan for the treatment of amyotrophic lateral sclerosis (ALS) did not meet its…
Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of Highly Differentiated Antibiotic for Severe Hospital Infections
Antabio SAS recently announces dosing of the first subjects in its Phase 1 clinical trial of MEM-ANT3310, a next- generation antibacterial combination that has been…
BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.
BriaCell Therapeutics Corp. recently announce it has entered into an arrangement agreement dated May 24, 2023, with BriaPro Therapeutics Corp. (SpinCo) pursuant to which certain…
Revvity Announces New License Agreement for Next-Generation Base Editing Technology
Revvity, Inc. recently announced a new license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a…
ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
ImmunOs Therapeutics AG recently announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia. IOS-1002 is a…
Alvotech & Advanz Pharma Extend Strategic Partnership to Commercialize Five Proposed Biosimilars in Europe
Alvotech and Advanz Pharma recently announced the companies have entered into an exclusive partnership agreement regarding the supply and commercialization of five biosimilar candidates in…
Pyxis Oncology to Acquire Apexigen
Pyxis Oncology, Inc. and Apexigen, Inc. recently announced a definitive agreement by which Pyxis Oncology will acquire Apexigen in an all-stock transaction for an implied value of….
Eloxx Pharmaceuticals to Advance ELX-02 Into Pivotal Trial for the Treatment of Alport Syndrome With Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study
Eloxx Pharmaceuticals, Inc. recently announced the company intends to advance ELX-02 into a pivotal trial for the treatment of Alport syndrome with nonsense mutations, following…
Valo Therapeutics Announces First Patient Dosed With PeptiCRAd-1 - Innovative Immuno-Oncology
Valo Therapeutics Oy (ValoTx) recently announced the first patient has been treated in its Phase 1 trial of PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus) in three tumor….
AnaMar Announces Positive Phase 1 Data for its Phase 2 Ready Compound for Treating Fibrosis
AnaMar, a clinical-stage biotech company developing a first-in-class, peripheral 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine, recently announced positive results from its Phase…
Ocean Biomedical, Inc. Announces Patent Award for Novel Cancer Immunotherapy Treatment Granted for Prostate Cancer, Colon Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma & Lung Cancer
Ocean Biomedical recently announced its Scientific Co-founder, Dr. Jack A. Elias, MD, has been issued a broad patent for his cancer immunotherapy discovery related to…
Roquette Announces Strategic Investment & Innovation Agreement With Beren Therapeutics P.B.C.
Roquette recently announce a strategic investment with Beren Therapeutics P.B.C., and the launch of an innovation agreement to expand the full potential of Beren’s cyclodextrin technologies and their medicinal….
Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease
Vega Therapeutics, Inc. recently announced the US FDA has granted the company orphan drug designation for VGA039 for the treatment of the rare bleeding disorder,…
AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration & Diabetic Macular Edema
AiViva Biopharma Inc. recently announced it has begun a Phase 1 trial and completed dosing the first cohort of patients diagnosed with wet age-related macular…
Oculis Announces Positive Top Line Results From DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema With OCS-01 Eye Drops
Oculis Holding AG recently announced positive top line results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 eye drops in Diabetic Macular…
NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors
NeuBase Therapeutics, Inc. recently announced a broad set of preclinical safety and efficiency data for its Stealth Editors development program that demonstrate the ability to achieve…
